The three-day agenda for the 6th Chronic Kidney Disease (CKD) Drug development Summit has been announced.
Taking place March 19-21, 2024 in Boston, M.A., this year’s program features an impressive roster of over 60 speakers from across the industry who’ll feature across three tracks of content:
- Target discovery and preclinical CKD models
- Exploratory biomarkers and early clinical innovation
- Regulatory-accepted clinical endpoints and outcomes research
Over 60 expert speakers will bring their industry knowledge and strategic expertise to the 2024 program, including:
- Aliza Thompson, Deputy Director, Division of Cardiology & Nephrology, FDA
- Achim Obergfell, Global Medical Head Nephrology, CSL Vifor
- Bhupinder Singh, Chief Medical Officer, Renibus Therapeutics
- Carolina Aldworth, Senior Medical Director, Novartis
- Charles Lee, Executive Director, Regulatory Affairs, Cardiovascular, Renal & Metabolism, AstraZeneca
- Katherine Garlo, Director, Global Medical Sciences, Alexion
- Stephen Elliman, Chief Scientific Officer, Orbsen Therapeutics
Also joining the speaker line-up is Suhail Tahir, senior scientist at Sanofi, who said:
“I find the CKD summit 2024 a rich opportunity to exchange the latest information on novel therapeutic and diagnostic targets, best practices, and new technologies from top leaders in the industries. I am hopeful to gain & provide valuable insights to advance kidney research, innovation, and drug development.”
To find out more about the speaker line-up, visit the website.
The Summit will also host the inaugural IgA Nephropathy Seminar Day, designed to deepen understanding of pathophysiology and genetic architecture to explore new targets, discover the latest complement, APRIL and BlyS clinical data, and discuss the integration of emerging IgAN treatments into evolving care standards with Calliditas, Otsuka, Novartis, Genentech, Takeda, Vera Therapeutics, Alexion and more.
For more information on the program, tickets and more, visit www.ckd3-summit.com